头颈部鳞状细胞癌的药物基因组学全景指导精准肿瘤治疗
研究建立56例头颈部鳞状细胞癌(HNSCC)患者来源细胞(PDC),对2248种化合物进行三层次高通量药物筛选并整合基因组与转录组分析,预测并验证了KRT18低表达对应非德拉替尼、IL6R活化对应米托蒽醌等药物重定位标志物,证实ITGB1高表达导致多西他赛耐药并在2期临床试验中验证其预测价值。
要点
- 56例HNSCC PDC保留原肿瘤分子特征,用于高通量药敏与生物标志物发现。
- KRT18低表达HNSCC对应非德拉替尼敏感,IL6R活化对应米托蒽醌敏感。
- ITGB1高表达导致多西他赛耐药,并在2期临床试验中验证其预测价值。
核心结论
- HNSCC细胞资源及药物基因组学图谱可用于生物标志物发现和指导HNSCC精准肿瘤治疗。
研究设计与样本
- 建立56例HNSCC患者来源细胞(PDC),并另用18株永生化细胞系,对2248种化合物进行三层次高通量药物筛选。
- 整合基因组、转录组和药理学分析以预测生物标志物、基因-药物关联并验证标志物。
主要发现
- PDC药敏预测与匹配患者对标准临床用药的反应一致。
- 低KRT18表达HNSCC病例对应JAK2抑制剂非德拉替尼,IL6R活化HNSCC病例对应拓扑异构酶抑制剂米托蒽醌。
- ITGB1高表达引发对多西他赛的治疗耐药,SOD1高表达赋予对阿法替尼的耐药。
关键数值与推荐
- 在2期临床试验中验证ITGB1作为多西他赛疗效预测生物标志物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Head and neck squamous cell carcinoma (HNSCC) is a common and frequently lethal cancer with few therapeutic options. In particular, there are few effective targeted therapies. Development of highly effective therapeutic strategies tailored to patients with HNSCC remains a pressing challenge. To address this, we present a pharmacogenomic study to facilitate precision treatments for patients with HNSCC. We established a large collection of 56 HNSCC patient-derived cells (PDCs), which recapitulated the molecular features of the original tumors. Pharmacological assessment of HNSCCs was conducted using a three-tiered high-throughput drug screening using 2248 compounds across these PDC models and an additional 18 immortalized cell lines. We integrated genomic, transcriptomic, and pharmacological analysis to predict biomarkers, gene-drug associations, and validated biomarkers. These results supported drug repurposing for multiple HNSCC subtypes, including the JAK2 inhibitor fedratinib, for low KRT18-expressing HNSCC cases, and the topoisomerase inhibitor mitoxantrone, for IL6R-activated HNSCC cases. Our results demonstrated concordance between susceptibility predictions from the PDCs and the matched patients' responses to standard clinical medication. Moreover, we identified and experimentally confirmed that high expression of ITGB1 elicited therapeutic resistance to docetaxel and high SOD1 expression conferred resistance to afatinib. We further validated ITGB1 as a predictive biomarker for the efficacy of docetaxel therapy in a phase 2 clinical trial. In summary, our study shows that this HNSCC cell resource, as well as the resulting pharmacogenomic profiles, is effective for biomarker discovery and for guiding precision oncology therapies in HNSCCs.
引用
- Gu Z, Yao Y, Yang G, et al. Pharmacogenomic landscape of head and neck squamous cell carcinoma informs precision oncology therapy. Sci Transl Med. 2022. PMID: 36070368. doi:10.1126/scitranslmed.abo5987
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。